Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study

Trial Profile

AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary)
  • Indications Tinnitus
  • Focus Adverse reactions
  • Acronyms AMPACT2
  • Sponsors Auris Medical
  • Most Recent Events

    • 24 Apr 2017 Recruitment for AMPACT2 has been completed and the open-label extension is not being offered to patients currently enrolling in the extended TACTT3 trial, as reported in an Auris Medical media release.
    • 24 Apr 2017 This trial has been conducted at the request of the US Food and Drug Administration (FDA) to generate safety data from chronic intermittent use of Keyzilen for up to 12 months, as reported in an Auris Medical media release.
    • 24 Apr 2017 Results published in the Auris Medical Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top